Emeryville, California, March 17, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies for solid tumors, today announced that it has
Emeryville, California, March 3, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, February 20, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, February 18, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, December 3, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new
Emeryville, California, October 31, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced the presentation
– POTENTIAL TO ACCELERATE APPLICATION OF T-CELL THERAPY TO OTHER SOLID TUMORS Emeryville, California, August 5, 2019 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical
– POTENTIAL TO IMPROVE EFFICACY OF T-CELL AND IMMUNE CHECKPOINT BLOCKADE THERAPIES IN SOLID TUMORS Emeryville, California, April 15, 2019 – Eureka Therapeutics, Inc., a clinical
– POTENTIAL TO TARGET GPRC5D IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER BCMA-TARGETED THERAPY Emeryville, California, March 27, 2019 – Eureka Therapeutics, Inc., a clinical stage
EMERYVILLE, California, February 11, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.